Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | Mexico | Healthcare | Pharmaceuticals | MX$12.32T | 57.9x | 0.76 | MX$13,783.55 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
J&J | Mexico | Healthcare | Pharmaceuticals | MX$7.08T | 16.9x | -0.4 | MX$2,948.69 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie | Mexico | Healthcare | Pharmaceuticals | MX$6.23T | 78.2x | -2.57 | MX$3,494 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk | Mexico | Healthcare | Pharmaceuticals | MX$5.79T | 19x | 1.01 | MX$1,294 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | Mexico | Healthcare | Pharmaceuticals | MX$4.89T | 26.5x | -0.9 | MX$6,035.68 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astrazeneca DRC | Mexico | Healthcare | Pharmaceuticals | MX$4.21T | 28.1x | 1.2 | MX$1,345 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | Mexico | Healthcare | Pharmaceuticals | MX$4.17T | 16.9x | -1.24 | MX$2,092.19 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck&Co | Mexico | Healthcare | Pharmaceuticals | MX$3.75T | 11.3x | 0.02 | MX$1,495 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Mexico | Healthcare | Pharmaceuticals | MX$2.81T | 24.6x | 0.44 | MX$5,300 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Mexico | Healthcare | Pharmaceuticals | MX$2.57T | 22.5x | 0.02 | MX$1,982 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Mexico | Healthcare | Pharmaceuticals | MX$2.55T | 16.8x | 0.01 | MX$449.98 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | Mexico | Healthcare | Pharmaceuticals | MX$2.45T | 18.5x | 0.45 | MX$1,003 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vertex Pharma | Mexico | Healthcare | Pharmaceuticals | MX$2.15T | -113.5x | 0.91 | MX$8,350 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol-Myers Squibb | Mexico | Healthcare | Pharmaceuticals | MX$1.83T | 17.6x | 0.09 | MX$930 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
McKesson | Mexico | Healthcare | Pharmaceuticals | MX$1.72T | 27.7x | 1.85 | MX$13,954 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | Mexico | Healthcare | Pharmaceuticals | MX$1.51T | 18.5x | -0.59 | MX$689.12 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bayer | Mexico | Healthcare | Pharmaceuticals | MX$488.41B | -6.7x | 1.48 | MX$492.21 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Teva DRC | Mexico | Healthcare | Pharmaceuticals | MX$374.24B | -15.8x | 0.09 | MX$325 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols Pref | Mexico | Healthcare | Pharmaceuticals | MX$121.67B | 31x | MX$126.63 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Bausch Health | Mexico | Healthcare | Pharmaceuticals | MX$33.61B | -48.8x | -0.46 | MX$139 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genomma Lab Int | Mexico | Healthcare | Pharmaceuticals | MX$20.66B | 9.4x | 0.09 | MX$21.24 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.7% Upside | Upgrade to Pro+ |